Impact of Staphylococcus Aureus on Folliculitis Decalvans

Role of Staphylococcus Aureus on Folliculitis Decalvans. A Comparative Bacteriological Study.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02157688

Acronym

SAFE

Enrollment

Registered

2014-06-06

Start date

2014-03-31

Completion date

2015-03-31

Last updated

2016-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Folliculitis Decalvans, Staphylococcus Aureus

Keywords

folliculitis decalvans, Staphylococcus Aureus, antibiotics

Brief summary

The folliculitis decalvans (FD) is an orphan disease , common in consultation specialized on scalp. This disease is currently not curable, responsible for significant for patients. The pathophysiology is poorly understood, Staphylococcus aureus (SA) appears to play a role, never previously studied, and the study will attempt to clarify it. Controversies in the literature on the pathophysiological hypotheses can be summed up as follows : FD is it an infectious folliculitis where SA (almost always found on the lesions plays a direct role possibly aided by a lack of local immune protection , or is it a pustular inflammatory unknown cause where the SA has no direct role but is a cofactor or a simple germ superinfection. Our study has plans to bring new evidence to help decide between these two opposite but not mutually exclusive concepts .

Interventions

OTHERno intervention : case control study

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adult (\>18 yo) * Alopecia * folliculitis decalvans * At least 6 months of evolution * no antibiotics * presence of pustules and crusts * Adult (\>18 yo)

Exclusion criteria

* immunosuppression * pregnancy

Design outcomes

Primary

Measure	Time frame	Description
presence of Staphylococcus Aureus in cutaneous biopsies (at least one colony)	1 day	The primary endpoint is the presence of Staphylococcus Aureus in cutaneous biopsies before any therapy and notably antibiotics.

Secondary

Measure	Time frame
presence of Staphylococcus Aureus in cutaneous biopsies (at least one colony) after treatment	10 weeks
presence of Staphylococcus Aureus in nasal swab (at least one colony)	1 day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026